title: Pancreatic cancer: new hopes for early detection and a future screening tool?
abstract: Given the overall poor prognosis of patients with pancreatic cancer, there has always been an interest in early screening and primary prevention. An abstract presented in ASCO 2014 by Orlowski et al. introduced the potential use of an elevated serum procarboxypeptidase A (PCPA) and high ratios of PCPA to free carboxypeptidase A (FCPA) in enhancing the diagnostic efficacy of pancreatic cancer either alone or with CA19-9 (Abstract #4118).
authors: Tufts University School of Medicine. Boston, MA, USA. neljurdi@tuftsmedicalcenter.org.
authors: Najla H
authors: NH
authors: El-Jurdi
authors: Muhammad Wasif
authors: MW
authors: Saif
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood; D043422:Carboxypeptidases A / Q000097:blood; D055088:Early Detection of Cancer / Q000379:methods* / Q000639:trends; D005544:Forecasting; D006801:Humans; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000175:diagnosis*; D012680:Sensitivity and Specificity
chemical_list: D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D043422:Carboxypeptidases A